Theralink Technologies, Inc. (THER) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Golden, CO, United States. The current CEO is Michael I. Ruxin.
THER has IPO date of 2010-04-01, 16 full-time employees, listed on the Other OTC, a market capitalization of $615.15K.
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. The company is headquartered in Golden, Colorado.
